Skip to content. | Skip to navigation

Personal tools


Managing bodies

logo Inserm      logo cnrslogo ENSL       logo ucb1

Secondary managing bodies

logo ENSL logo ucb1

You are here: Home / Teams / Lina B - VirPath / M. Rosa-Calatrava group / Actualités / News 2020

News 2020


2020, December the 8th

Délivrance française de notre brevet d’invention (WO2018/073549) sur de nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus.

L’invention concerne le repositionnement de molécules pour de nouvelles indications antivirales prophylactiques et thérapeutiques contre le coronavirus MERS-CoV (Middle East Respiratory Syndrome-related Coronavirus) chez l’homme et chez les animaux. Signia Therapeutics possède les droits internationaux exclusifs pour ce brevet d’invention.


2020, October the 12th

2020, August the 14th

Reportage du journal du CNRS sur la recherche d'un médicament efficace contre le virus SARS-CoV-2 en un temps record. Une course contre la montre qui se déroule in vitro, in vivo et même... in silico.

2020, July the 29th

Our article on human RSV-induced immune signature of infection is now published in The Journal of Infectious Diseases.

In this study, we applied a tailored transcriptomics workflow to exploit nasal wash samples from children who tested positive for HRSV. Our analysis revealed a characteristic immune signature as a direct reflection of HRSV pathogenesis and highlighted putative biomarkers of interest such as IP-10, TMEM190, MCEMP1 or TIMM23.


2020, July the 22nd

Notre laboratoire VirPath est fier d’avoir participé à ce travail collaboratif mené par le CEA, l'Inserm, l'Institut Pasteur, le CNRS - Centre national de la recherche scientifique, l’Université de Paris-Saclay, APHM (Assistance Publique - Hopitaux de Marseille) et Aix-Marseille Université, sous l’égide du consortium multidisciplinaire REACTing. Nos modèles d’infection en épithélium respiratoire humain reconstitué ont été prédictifs des résultats obtenus en modèle de primate, qui démontrent que l’hydroxychloroquine n’a pas d’efficacité antivirale in vivo, et ce malgré une exposition pulmonaire importante.


2020, July the 21st

In this study, we provide evidence on the antiviral efficacy of Remdesivir and the therapeutic potential of the Remdesivir-Diltiazem combination as a rapidly available and promising option to respond to the current medical need imposed by COVID-19. This combination of a virus-directed plus a host-directed drug stimulating endogenous expression of type I and type III interferons could not only result in enhanced antiviral and/or immunomodulatory effects, but also reduce the therapeutic doses of chemotherapeutic agents targeting nucleic acid synthesis in order to minimize putative adverse side effects.

2020, July the 16th

Our comment on France's COVID-19 response is now published in The Lancet.


2020, July the 15th

Our article on the in vitro evaluation of compounds, known for their cellular broad-spectrum activities, together with drugs that are under evaluation in clinical trials for COVID-19 patients is now published in Antiviral Research.

In this study, we report the antiviral effect of remdesivir, lopinavir, chloroquine, umifenovir, berberine and cyclosporine A in Vero E6 cells model of SARS-CoV-2 infection. Virus-directed plus host-directed drug combinations were also investigated. We report strong antagonism for remdesivir/berberine and high level of synergy for remdesivir/diltiazem drug combinations. These combinations of host-directed drugs with direct acting antivirals open interesting avenues for the treatment of COVID-19.




2020, March the 14th


The aim of this R&D project is to develop and characterize a model of metapneumovirus (hMPV) infection in the non-human primate (NHP) Cynomolgus in order to meet current unmet needs for the development and preclinical evaluation of prophylactic or therapeutic solutions against these respiratory infections, which are a major global health and economic issue.

These viral infections are the main cause of bronchiolitis and pneumonia in young children (33 million children under 5 infected per year, 3 million hospitalizations per year, including 2% deaths). In particular, this project aims to exploit the PNH model developed to validate the preclinical efficacy of a drug already repositioned by Signia Therapeutics as a new-generation antiviral against hMPV viruses. The project is fully in line with the Cynbiome programme (PIA3), which brings together a number of regional players in the health DOMEX.

The aims of the project are (i) to develop, validate and characterize a PNH model of hMPV infection and (ii) to use this model to validate the preclinical efficacy of a new nebulized delivery method for a drug repositioned by Signia Therapeutics (Dilitiazem) as a new-generation antiviral (patent WO/2019/224489 A1) and to accelerate its transfer to phase 2 clinical trials (the project's ultimate aim).

The consortium is made up of three players based in the Auvergne-Rhône-Alpes region, whose complementarity will be used to innovate: Cynbiose and Signia Therapeutics are the industrial partners and the VirPath laboratory is the academic partner.